Press Release
June 9, 2016

PRESS: Sandoz Enbrel Copycat Next Biosimilar To Get Panel Treatment (Scrip)

William James, a partner in Goodwin's IP Litigation Group, explains why the FDA elected to take Sandoz Inc.'s latest application for its etanercept biosimilar to an advisory committee to get its advice on whether to license the product.

Read the full Scrip article here.